Literature DB >> 19602461

Chromosomal changes in aggressive breast cancers with basal-like features.

Wayne Yu1, Yasmine Kanaan, Young Kyung Bae, Young-Kyung Baed, Edward Gabrielson.   

Abstract

Using high-resolution oligonucleotide comparative genomic hybridization arrays, we evaluated chromosomal copy number changes in a series of 16 breast cancers, selected on the basis of highly similar pathologic and molecular features characteristic of the "basal-like" phenotype. Each of these cancers showed numerous gains and losses, reflecting multiple chromosomal rearrangements during the development of these high-grade cancers. Chromosomal losses were particularly prevalent on chromosomal arms 5q, 8p, 9q, 12q, 17p, 19p, and Xq, and gains were commonly seen on chromosomal arms 1q, 8q, and 17q. The regions of high-level amplification (copy number change more than eightfold) on 4q12, 8q23.3, 19p12, and 19q13.2 were particularly remarkable. These regions included candidate oncogenes cKIT, JUND, and AKT2, and immunohistochemistry confirmed that these particular genes were highly expressed in the cancers harboring the specific amplifications. Each of these amplifications was observed only in individual cases, however, and no particular chromosomal alteration appeared to generally characterize this group of cancers. Thus, genomic changes among breast cancers with basal-like features appear to be very heterogeneous. Distinct high-level amplifications may provide new targets for treating some of these cancers, but copy number changes do not reveal a distinctive genomic fingerprint for this proposed class of breast cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602461      PMCID: PMC2768045          DOI: 10.1016/j.cancergencyto.2009.03.017

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  34 in total

1.  Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast.

Authors:  C Jones; M P Foschini; R Chaggar; Y J Lu; D Wells; J M Shipley; V Eusebi; S R Lakhani
Journal:  Lab Invest       Date:  2000-06       Impact factor: 5.662

2.  A proposed histochemical and electron microscopic classification of human breast cancer according to cell of origin.

Authors:  T M Murad
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

3.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

4.  cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.

Authors:  L M Smith; S C Wise; D T Hendricks; A L Sabichi; T Bos; P Reddy; P H Brown; M J Birrer
Journal:  Oncogene       Date:  1999-10-28       Impact factor: 9.867

5.  Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.

Authors:  Eberhard Korsching; Jens Packeisen; Konstantin Agelopoulos; Martin Eisenacher; Reinhard Voss; Jorma Isola; Paul J van Diest; Burkhard Brandt; Werner Boecker; Horst Buerger
Journal:  Lab Invest       Date:  2002-11       Impact factor: 5.662

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

8.  KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

Authors:  Ronald Simon; Soti Panussis; Robert Maurer; Hanspeter Spichtin; Kathrin Glatz; Coya Tapia; Martina Mirlacher; Alex Rufle; Joachim Torhorst; Guido Sauter
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

9.  Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers.

Authors:  Zhigang C Wang; Ming Lin; Lee-Jen Wei; Cheng Li; Alexander Miron; Gabriella Lodeiro; Lyndsay Harris; Sridhar Ramaswamy; David M Tanenbaum; Matthew Meyerson; James D Iglehart; Andrea Richardson
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

10.  Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes.

Authors:  Chris Jones; Emily Ford; Cheryl Gillett; Ken Ryder; Samantha Merrett; Jorge S Reis-Filho; Laura G Fulford; Andrew Hanby; Sunil R Lakhani
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

View more
  24 in total

Review 1.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

2.  Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.

Authors:  Helga Bergholtz; Tonje G Lien; David M Swanson; Arnoldo Frigessi; Maria Grazia Daidone; Jörg Tost; Fredrik Wärnberg; Therese Sørlie
Journal:  NPJ Breast Cancer       Date:  2020-06-17

3.  Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women.

Authors:  Ming-xi Jing; Xiao-yun Mao; Chao Li; Jing Wei; Chong Liu; Feng Jin
Journal:  Tumour Biol       Date:  2011-04-06

4.  The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer.

Authors:  Norma E Ramirez; Zhonghua Zhang; Aasakiran Madamanchi; Kelli L Boyd; Lynda D O'Rear; Abudi Nashabi; Zhengzi Li; William D Dupont; Andries Zijlstra; Mary M Zutter
Journal:  J Clin Invest       Date:  2010-12-06       Impact factor: 14.808

5.  Gene copy number variation in male breast cancer by aCGH.

Authors:  Stefania Tommasi; Anita Mangia; Giuseppina Iannelli; Patrizia Chiarappa; Elena Rossi; Laura Ottini; Marcella Mottolese; Wainer Zoli; Orsetta Zuffardi; Angelo Paradiso
Journal:  Cell Oncol (Dordr)       Date:  2011-05-06       Impact factor: 6.730

6.  Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer.

Authors:  Sameer S Bajikar; Chun-Chao Wang; Michael A Borten; Elizabeth J Pereira; Kristen A Atkins; Kevin A Janes
Journal:  Dev Cell       Date:  2017-11-20       Impact factor: 12.270

7.  Association between apolipoprotein E genotype and cancer susceptibility: a meta-analysis.

Authors:  R Anand; S S Prakash; R Veeramanikandan; Richard Kirubakaran
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-05       Impact factor: 4.553

8.  Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.

Authors:  Darshan S Chandrashekar; Balabhadrapatruni V S K Chakravarthi; Alyncia D Robinson; Joshua C Anderson; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Marie-Lisa Eich; Akhilesh Kumar Bajpai; Sravanthi Davuluri; Maya S Guru; Arjun S Guru; Gurudatta Naik; Deborah L Della Manna; Kshitish K Acharya; Shannon Carskadon; Upender Manne; David K Crossman; James E Ferguson; William E Grizzle; Nallasivam Palanisamy; Christopher D Willey; Michael R Crowley; George J Netto; Eddy S Yang; Sooryanarayana Varambally; Guru Sonpavde
Journal:  Oncogene       Date:  2020-03-30       Impact factor: 9.867

9.  PAK4-6 in cancer and neuronal development.

Authors:  Audrey Minden
Journal:  Cell Logist       Date:  2012-04-01

10.  The pak4 protein kinase in breast cancer.

Authors:  Audrey Minden
Journal:  ISRN Oncol       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.